Skye Bioscience (SKYE) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
26 May, 2026Opening remarks and agenda
Meeting called to order at 10:00 A.M. Pacific Time on May 26, 2026, with board nominees and independent auditor present.
Inspector of Election appointed and oath filed; meeting held per notice and proxy statement.
Proof of mailing of proxy materials and notice to stockholders confirmed.
Shareholder proposals
Four proposals presented: election of six directors, ratification of auditor, amendment to increase authorized shares, and advisory vote on executive compensation.
Overview of voting outcomes
Quorum established with 66.98% of shares represented.
All six director nominees elected for one-year terms expiring at the 2027 meeting.
Auditor appointment ratified for fiscal year ending December 31, 2026.
Amendment to increase authorized shares from 100 million to 300 million approved.
Advisory approval of executive compensation passed.
Final vote results to be reported in a Form 8-K filing within four business days.
Latest events from Skye Bioscience
- Nimacimab plus semaglutide achieved 22.3% weight loss at 52 weeks with strong safety and scalability.SKYE
Corporate presentation14 May 2026 - Q1 net loss reached $12.5M as nimacimab combo therapy advanced amid funding risks.SKYE
Q1 202611 May 2026 - Nimacimab plus semaglutide delivers durable, additive weight loss; cash runway through Q4 2026.SKYE
Q4 20252 May 2026 - Key votes include director elections, auditor ratification, share increase, and say-on-pay.SKYE
Proxy filing16 Apr 2026 - Shareholders will vote on director elections, auditor ratification, share increase, and executive pay.SKYE
Proxy filing16 Apr 2026 - Nimacimab plus semaglutide delivers durable, significant weight loss with strong safety and commercial potential.SKYE
Corporate presentation7 Apr 2026 - Shareholders to vote on board elections, auditor ratification, share increase, and executive pay.SKYE
Proxy filing6 Apr 2026 - Shareholders to vote on board elections, auditor, share increase, and executive pay amid clinical progress.SKYE
Proxy filing6 Apr 2026 - Nimacimab plus semaglutide delivers superior, durable weight loss with strong safety and financial backing.SKYE
Corporate presentation10 Mar 2026